Clincosm LogoSign in Get a demo

Cognitive, Emotional and Behavioural Impairments in Patients After Sars-Cov2 Infection

Sponsor
Ospedale Generale Di Zona Moriggia-Pelascini (Other)
Overall Status
Completed
CT.gov ID
NCT05143320
Collaborator
(none)
29
Enrollment
1
Location
9.7
Actual Duration (Months)
3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Recent studies suggest cognitive, emotional and behavioural impairments occur in patients after SARS-CoV-2 infection. Problems with memory, attention, information processing and executive functions are particularly prevalent in these patients, probably due to hypothesised sensitivity of the hippocampus to the virus. Cognitive impairment is also present in patients with no neurological, neuropsychological and neuropsychiatric history. Therefore, the aim of the present study is to describe neuropsychological and neuropsychiatric features in patients recovered from moderate to severe forms of Covid-19 some weeks after hospital dismission.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    29 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Cognitive and Neuropsychiatric Features of COVID-19 Patients After Hospital Dismission: an Italian Sample.
    Actual Study Start Date :
    Jan 8, 2021
    Actual Primary Completion Date :
    May 21, 2021
    Actual Study Completion Date :
    Oct 29, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    Covid+
    Covid-

    Outcome Measures

    Primary Outcome Measures

    1. Cognitive and neuropsychiatirc symptoms in Covid-19 patients [About 20 days after hospital dismission]

      Prevalence of neuropsychological and neuropsychiatric impairment in patients after hospitalization in patients with Sars-Cov2 infection.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    30 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Positive PCR from nasopharyngeal swab

    • No ICU admission

    Exclusion Criteria:

    • Diagnosis of neurologic or psychiatric disorders;

    • Previous cognitive impairment;

    • Other medical conditions negatively affecting the cognitive status.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 "Moriggia Pelascini" Hospital Gravedona Como Italy 22015

    Sponsors and Collaborators

    • Ospedale Generale Di Zona Moriggia-Pelascini

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ospedale Generale Di Zona Moriggia-Pelascini
    ClinicalTrials.gov Identifier:
    NCT05143320
    Other Study ID Numbers:
    • NPS impairment in Covid-19
    First Posted:
    Dec 3, 2021
    Last Update Posted:
    Dec 3, 2021
    Last Verified:
    Dec 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ospedale Generale Di Zona Moriggia-Pelascini
    Covid-19
    Cognition
    Teleneuropsychology
    Memory
    Executive Functions
    Additional relevant MeSH terms:
    Infections
    COVID-19

    Study Results

    No Results Posted as of Dec 3, 2021